SCHEMBL1694022

SCHEMBL1694022

CC(CCCN)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21209464 1.00
SCHEMBL11924541 1.00
Hydrochloric Acid SCHEMBL3507715 0.98 GABRR1 (0.70)
SCHEMBL39271 0.93 GABRR1 (0.70)
SCHEMBL17974330 0.93 GABRR1 (0.70)
SCHEMBL12173395 0.93 GABRR1 (0.70)
SCHEMBL1872640 0.91 GABRR1 (0.67)
SCHEMBL4017002 0.91 GABRR1 (0.67)
SCHEMBL10869353 0.91 GABRR1 (0.67)
SCHEMBL1882487 0.91 GABRR1 (0.67)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 CN claimed
US-20230278953-A1 WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY KLOTHO THERAPEUTICS, INC. 2023-09-07 US disclosed
US-20230278953-A1 WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY KLOTHO THERAPEUTICS, INC. 2023-09-07 US disclosed
CN-110382084-A Process for removing acid gases from fluid streams 巴斯夫欧洲公司 2019-10-25 CN disclosed
US-20170045526-A1 MASS LABELS ELECTROPHORETICS LIMITED (GB) 2017-02-16 US disclosed
US-9567655-B2 Processes for the separation of ores GEORGIA-PACIFIC CHEMICALS LLC (US) 2017-02-14 US disclosed
EP-2964616-A1 NEPRILYSIN INHIBITORS Theravance Biopharma R&D IP, LLC (US) 2016-01-13 EP disclosed
EP-2879673-A1 COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS Biogen Idec MA Inc. (US) 2015-06-10 EP disclosed
US-8871922-B2 Cellulose materials with novel properties FPINNOVATIONS (CA) 2014-10-28 US disclosed
WO-2014138053-A1 NEPRILYSIN INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2014-09-12 WO disclosed
US-20090301972-A1 MATERIALS AND PROCESS FOR ENHANCING SELECTIVE SEPARATIONS GEORGIA-PACIFIC CHEMICALS LLC (US) 2009-12-10 US disclosed
WO-2009149334-A2 MATERIALS AND PROCESS FOR ENHANCING SELECTIVE SEPARATIONS GEORGIA-PACIFIC CHEMICALS LLC (US) 2009-12-10 WO disclosed
US-7109160-B1 Peptides containing the motif IGD and their use as cell migration modulators UNIVERSITY OF DUNDEE (GB) 2006-09-19 US disclosed
EP-1697337-A2 ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS Astellas Pharma Inc. (JP) 2006-09-06 EP disclosed
WO-2005061475-A2 ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS ASTELLAS PHARMA INC. (JP) 2005-07-07 WO disclosed
WO-1996015789-A1 NON-PEPTIDIC SURROGATES OF ARG-GLY-ASP SEQUENCE AND USE YEDA RESEARCH AND DEVELOPMENT CO., LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) 1996-05-30 WO disclosed
EP-0186083-A2 N-(2-Hyxdroxyalkyl)-amino acids and their derivatives, process for their preparation and pharmaceutical compositions containing them ASTA Pharma AG (DE) 1986-07-02 EP disclosed
EP-0025370-B1 PREPARATION OF FLUORINATED METHYLAMINOALKANOIC ACIDS, PROCESS INTERMEDIATES AND THEIR PREPARATION MERRELL TORAUDE ET COMPAGNIE (FR) 1983-05-11 EP disclosed
US-4353828-A Preparation of fluorinated methyl aminoalkanoic acids and novel process intermediates MERRELL TORAUDE ET COMPAGNIE (FR) 1982-10-12 US disclosed
EP-0025370-A2 Preparation of fluorinated methylaminoalkanoic acids, process intermediates and their preparation MERRELL TORAUDE ET COMPAGNIE (FR) 1981-03-18 EP disclosed